Jump to content


Did you know that exercise increases inflammation in systemic sclerosis?


Photo

Daval AIMSPRO as monotherapy in scleroderma yields positive results.


  • Please log in to reply
No replies to this topic

#1 Joelf

Joelf

    Star Ruby Member

  • ISN Root Admin
  • PipPipPipPipPipPipPipPipPipPipPipPipPip
  • 4,610 posts
  • Location:West Sussex

Posted 08 November 2011 - 09:18 AM

Daval AIMSPRO as monotherapy in scleroderma yields positive results.

The double-blind placebo-controlled phase II clinical study to assess the safety and tolerability of AIMSPRO as a monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma) yielded positive results. PBR Clinical Trials. 10/11/11. (Also see: Clinical Trials: Positive)

This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Jo Frowde
ISN Assistant Webmaster

SD World Webmaster
ISN Sclero Forums Manager
ISN News Manager

ISN Hotline Support Specialist
ISN Chat Host
International Scleroderma Network (ISN)